Dr. William Langridge is currently working as a Professor in the Department of Division of Biochemistry, Loma Linda University , U.S.A. His research interests includes development of protein adjuvants to enhance subunit vaccine protection and therapeutic treatment for infectious and inflammatory autoimmune diseases with the goal of decreasing present disparities in health care. He  is serving as an editorial member and reviewer of several international reputed journals. Dr. William Langridge is the member of many international affiliations. He has successfully completed his Administrative responsibilities. He  has authored of many research articles/books related to development of protein adjuvants to enhance subunit vaccine protection and therapeutic treatment for infectious and inflammatory autoimmune diseases with the goal of decreasing present disparities in health care.

Dr. Langridge's research interests in the Center for Health Disparities and Molecular Medicine are focused on development of protein adjuvants to enhance subunit vaccine protection and therapeutic treatment for infectious and inflammatory autoimmune diseases with the goal of decreasing present disparities in health care. (a) Our laboratory is developing multi-component mucosal subunit vaccines, composed of genes encoding bacterial enterotoxin B subunit adjuvant molecules linked to pathogen antigens to provide immunoenhanced antigen conjugates that stimulate innate and adaptive immune responses that generate enhanced protection against viral and bacterial pathogens such as Rotavirus, Enterotoxigenic E. coli, Cholera, Norwalk virus, Anthrax, HIV-1, Hepatitis B, and Rabies virus. Innovations leading to improvements in subunit vaccine efficacy will reduce the cost of protection against infectious diseases and will help reduce health-care disparities among middle and lower socio-economic groups. (b) Dr. Langridge’s laboratory is exploring adjuvant stimulated subunit vaccine protection and therapy for suppression of diabetes inflammation. Bacterial enterotoxin B subunit linked pancreatic islet autoantigen fusion proteins activate mechanisms of immunological tolerance to suppress the onset of diabetes. DNA and virus-based diabetes vaccine development combines recombinant plasmid DNA priming with an attenuated vaccinia virus or transgenic edible plant boost. This heterologous prime-boost subunit vaccination strategy promises amplification of mucosal immune responses to subunit vaccines and is supported by an NIH award from NIDDK for immune suppression of inflammation based autoimmune diabetes. (c) In collaboration with Theresa Strong's lab at the University of Alabama, DNA and recombinant vaccinia virus subunit vaccines are under development for delivery of cholera toxin B subunit -fusions with the adenomatous polyposis coli (APC) and carcinoembryonic antigen (CEA) genes to break immune tolerance to CEA and APC marker proteins synthesized in colon adenomas. Increased immunogenicity of colon tumors will increase the effectiveness and lower the cost of colon cancer therapy, which will help to reduce the health-care disparity in the African-American population which is at a significantly higher risk for colon cancer. Dr. Langridge is a member of the faculty of the Loma Linda University School of Medicine, Center for Health Disparities and Molecular Medicine (CHDMM). Dr. Langridge received his doctorate in the biochemistry of animal development from the University of Massachusetts at Amherst, under the mentorship of Dr. Frank DeToma and completed his post-doctoral studies on the molecular biology of invertebrate viruses at the Boyce Thompson Institute in New York City under the mentorship of Dr. Donald Roberts. His graduate and post-doctoral studies were supported by graduate assistantships from Amherst and Mount Holyoke Colleges and a Genetics Training Grant awarded by the National Institutes of Health (NIH). Dr. Langridge's main research focus is on mechanisms of chronic inflammation underlying the onset and development of autoimmune diseases, specifically Type 1 and Type 2 diabetes. Dr. Langridge is the principal investigator on NIAID and NIDDK NIH awards focused on the development of preventive and therapeutic strategies for Type 1 diabetes and infectious enteric bacterial and viral diseases responsible for extensive loss of life of children in developing countries around the world. During Dr. Langridge's professional career he has served as a panelist for the National Institutes of Health, Department of Health and Human Services, Bethesda, MD. Dr. Langridge has received research funding from the National Institutes of Health (NIDDK, NIAID), the National Science Foundation (NSF), the National Science and Engineering Research Council of Canada, (NSERC) and the University of Alberta, Alberta, Canada and Loma Linda University in Southern California.